Atossa Therapeutics, Inc. (ATOS)
ATOSNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$2.03
-0.1000 (-4.69%) today
Closed, Nov 11, 4:00 PM ET
- Market cap
- $20.26m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.70 to $14.85
- Average volume
- –
- Previous close
- $2.13
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $17.50, +762.1% from here
Earnings
next estimate $-0.8600Next report
Mar 2026
+9.0%
Jun 2026
+8.7%
Sep 2026
+34.9%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$9.25m | -$11.44m | -$9.87m | -$8.69m |
| Net income | -$8.69m | -$10.94m | -$9.59m | -$8.49m |
News
8 latest- Atossa Therapeutics Q3 Loss Narrows; Expects (Z)-Endoxifen IND Clearance In Early 2027 RTTNews · 23 hours ago
- Atossa Plans CVR Tied To Potential Rare Pediatric Disease Voucher RTTNews · Sep 30, 2026
- Atossa Therapeutics Announces $16.5 Million Registered Direct Offering; Stock Down RTTNews · Jun 11, 2026
- Atossa Gets FDA Rare Pediatric Disease Tag For (Z)-Endoxifen In McCune-Albright Syndrome RTTNews · May 4, 2026
- Atossa Therapeutics (ATOS) Price Target Increased by 1,400.00% to 87.98Fintel · Feb 4, 2026
- Atossa Secures FDA Orphan Drug Designation For (Z)-Endoxifen In Duchenne Muscular Dystrophy RTTNews · Jan 16, 2026
- What's Driving Atossa's Premarket Momentum? RTTNews · Jan 16, 2026
- Ascendiant Capital Maintains Atossa Therapeutics (ATOS) Buy RecommendationFintel · Dec 8, 2025
The company
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need. The Company's lead product candidate, (Z)-endoxifen, is currently in development across several clinical settings. (Z)-Endoxifen is a potent Selective Estrogen Receptor Modulator/Degrader (SERM/D) with demonstrated activity across multiple mechanisms of interest. Atossa is evaluating its potential applications in oncology and rare diseases. The Company's proprietary oral formulation has shown a favorable safety profile and pharmacology distinct from tamoxifen, including ER-targeted effects and PKC inhibition. Atossa's (Z)-endoxifen is not approved for any indication.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- atossatherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.